Seres Therapeutics Inc. (Nasdaq: MCRB)

https://www.serestherapeutics.com

LinkedIn: https://linkedin.com/company/seres-tx

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and plans to initiate a clinical program with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. *

	Start	2016-01-11 existent
	Predecessor	Seres Health Inc.
	Industry	microbiomics
	Industry 2	SER-109 (Seres Therapeutics)
	Person	Shaff, Eric (Seres Therapeutics 201903 CEO)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	200 Sidney Street
	City	02139 Cambridge, MA
	Tel	+1-617-945-9626
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Seres Therapeutics, Inc.. (5/20/21). "Press Release: Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development". Cambridge, MA.

		Record changed: 2023-07-10